
|Videos|August 12, 2011
ASCO: Controversies in Phase I Clinical Trials
Author(s)Steve Joffe, MD
Steve Joffe, MD discusses the ethical challenges and controversies in phase I clinical cancer trials.
Advertisement
Steve Joffe, MD discusses the ethical challenges and controversies in phase I clinical cancer trials: how physicians should present these clinical trials to patients-phase I trials typically have very low response rates (5% to 10%)-and explain their purpose without exaggerating the likely results.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on CancerNetwork
1
Data Readouts to Watch at the 2026 ASCO Annual Meeting
2
Alpha DaRT Elicits 100% Local Disease Control in Pancreatic Cancer
3
101 Patient-Reported Outcomes (PROs) in Patients With ER+, HER2- Advanced Breast Cancer (ABC) Treated with Imlunestrant, Investigator’s Choice Standard Endocrine Therapy, or Imlunestrant+Abemaciclib: Results From the Phase III EMBER-3 Trial
4
Alpha DaRT Overcomes Anatomical Constraints in Inoperable Pancreatic Cancer
5






















































